
May 14 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O:
BIOCRYST ANNOUNCES FDA ACCEPTANCE OF NDA FOR ORLADEYO® (BEROTRALSTAT) ORAL GRANULES IN PATIENTS WITH HEREDITARY ANGIOEDEMA AGED 2 TO 11 YEARS
BIOCRYST PHARMACEUTICALS INC: FDA GRANTS PRIORITY REVIEW OF APPLICATION, WITH PDUFA TARGET ACTION DATE OF SEPTEMBER 12, 2025
BIOCRYST PHARMACEUTICALS: FILED LINE EXTENSION APPLICATION FOR USE OF ORLADEYO ORAL GRANULES IN PATIENTS WITH HAE AGED 2-11 YEARS WITH EMA